ReviewJournal of molecular histology2026
Protein acylation and bone metabolism: bidirectional crosstalk linking metabolic reprogramming to skeletal homeostasis.
Review in Journal of molecular histology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Protein acylation is an important class of post-translational modifications that uses acyl-coenzyme A (acyl-CoA) metabolites as donor substrates. Regulated by writers, erasers, and readers, these modifications dynamically control protein activity, stability, localization, and signaling, thereby linking cellular metabolism to functional adaptation. Bone homeostasis depends on the balance between osteoblast-mediated bone formation and osteoclast-driven bone resorption. Emerging evidence indicates that protein acylation is not only a regulator of skeletal remodeling, but also a metabolic sensor shaped by bone-cell reprogramming. In this review, we summarize the metabolic origins, regulatory enzymes, and skeletal functions of major acylation modifications, including acetylation, succinylation, lactylation, and palmitoylation. These modifications influence osteoblast differentiation, osteoclastogenesis, mitochondrial homeostasis, and microenvironmental adaptation through key targets such as Runx2, Osterix, p53, and superoxide dismutase 2 (SOD2). Conversely, metabolic transitions in bone cells, including enhanced glycolysis, mitochondrial activation, fatty acid oxidation, and tricarboxylic acid (TCA) cycle remodeling, reshape intracellular acyl-CoA availability and thereby alter cellular acylation patterns. This bidirectional crosstalk forms a dynamic metabolism-acylation-function axis whose dysregulation may contribute to osteoporosis, osteoarthritis, and other skeletal disorders. Understanding this regulatory network may provide candidate biomarkers and therapeutic targets for precision management of metabolic bone diseases.
Indexed as
Identifiers
42839118What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.